Annual EBIT
$24.28 M
+$54.62 M+180.05%
December 31, 2023
Summary
- As of March 10, 2025, RDHL annual earnings before interest & taxes is $24.28 million, with the most recent change of +$54.62 million (+180.05%) on December 31, 2023.
- During the last 3 years, RDHL annual EBIT has risen by +$88.01 million (+138.11%).
- RDHL annual EBIT is now at all-time high.
Performance
RDHL EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
N/A
June 1, 2024
Summary
- RDHL quarterly earnings before interest & taxes is not available.
Performance
RDHL Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBIT
N/A
June 1, 2024
Summary
- RDHL TTM earnings before interest & taxes is not available.
Performance
RDHL TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RDHL EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +180.1% | - | - |
| 3 y3 years | +138.1% | - | - |
| 5 y5 years | +162.6% | - | - |
RDHL EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +129.9% | ||||
| 5 y | 5-year | at high | +129.9% | ||||
| alltime | all time | at high | +129.9% |
RedHill Biopharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $24.28 M(-180.0%) | - | - |
| Jun 2023 | - | $2.69 M(-94.7%) | $47.13 M(+27.6%) |
| Mar 2023 | - | $50.66 M(-2300.8%) | $36.95 M(-221.8%) |
| Dec 2022 | -$30.34 M(-62.6%) | -$2.30 M(-41.2%) | -$30.34 M(-37.9%) |
| Sep 2022 | - | -$3.92 M(-47.7%) | -$48.81 M(-21.6%) |
| Jun 2022 | - | -$7.50 M(-54.9%) | -$62.28 M(-21.8%) |
| Mar 2022 | - | -$16.62 M(-20.0%) | -$79.65 M(-1.8%) |
| Dec 2021 | -$81.18 M(+27.4%) | -$20.78 M(+19.6%) | -$81.14 M(+0.9%) |
| Sep 2021 | - | -$17.38 M(-30.1%) | -$80.45 M(+3.8%) |
| Jun 2021 | - | -$24.87 M(+37.3%) | -$77.48 M(+19.2%) |
| Mar 2021 | - | -$18.11 M(-9.8%) | -$65.01 M(+2.1%) |
| Dec 2020 | -$63.72 M(+52.0%) | -$20.09 M(+39.3%) | -$63.70 M(+15.5%) |
| Sep 2020 | - | -$14.42 M(+16.3%) | -$55.16 M(+9.4%) |
| Jun 2020 | - | -$12.39 M(-26.2%) | -$50.42 M(+3.2%) |
| Mar 2020 | - | -$16.80 M(+45.4%) | -$48.86 M(+19.5%) |
| Dec 2019 | -$41.91 M(+8.0%) | -$11.55 M(+19.4%) | -$40.90 M(+4.2%) |
| Sep 2019 | - | -$9.67 M(-10.7%) | -$39.24 M(+0.2%) |
| Jun 2019 | - | -$10.83 M(+22.6%) | -$39.17 M(+3.8%) |
| Mar 2019 | - | -$8.84 M(-10.7%) | -$37.74 M(-2.6%) |
| Dec 2018 | -$38.82 M(-14.8%) | -$9.90 M(+3.1%) | -$38.76 M(-1.5%) |
| Sep 2018 | - | -$9.60 M(+2.1%) | -$39.34 M(-9.7%) |
| Jun 2018 | - | -$9.40 M(-4.7%) | -$43.56 M(-3.6%) |
| Mar 2018 | - | -$9.86 M(-5.9%) | -$45.17 M(+3.0%) |
| Dec 2017 | -$45.54 M | -$10.48 M(-24.1%) | -$43.86 M(+2.2%) |
| Sep 2017 | - | -$13.81 M(+25.4%) | -$42.92 M(+14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$11.02 M(+28.9%) | -$37.45 M(+13.6%) |
| Mar 2017 | - | -$8.55 M(-10.4%) | -$32.96 M(+10.1%) |
| Dec 2016 | -$30.54 M(+38.8%) | -$9.54 M(+14.3%) | -$29.94 M(+6.7%) |
| Sep 2016 | - | -$8.35 M(+27.8%) | -$28.05 M(+22.6%) |
| Jun 2016 | - | -$6.53 M(+18.2%) | -$22.88 M(+3.6%) |
| Mar 2016 | - | -$5.52 M(-27.8%) | -$22.07 M(+5.0%) |
| Dec 2015 | -$22.00 M(+106.6%) | -$7.65 M(+141.3%) | -$21.02 M(+11.7%) |
| Sep 2015 | - | -$3.17 M(-44.6%) | -$18.82 M(-3.6%) |
| Jun 2015 | - | -$5.72 M(+28.1%) | -$19.51 M(+9.8%) |
| Mar 2015 | - | -$4.47 M(-18.0%) | -$17.77 M(+79.2%) |
| Dec 2014 | -$10.65 M(-1.2%) | -$5.45 M(+41.0%) | -$9.92 M(+23.1%) |
| Sep 2014 | - | -$3.87 M(-2.9%) | -$8.06 M(+17.0%) |
| Jun 2014 | - | -$3.98 M(-217.7%) | -$6.89 M(+27.2%) |
| Mar 2014 | - | $3.38 M(-194.1%) | -$5.42 M(-49.7%) |
| Dec 2013 | -$10.77 M(+19.2%) | -$3.59 M(+33.3%) | -$10.77 M(+14.1%) |
| Sep 2013 | - | -$2.70 M(+7.5%) | -$9.44 M(+9.6%) |
| Jun 2013 | - | -$2.51 M(+27.1%) | -$8.61 M(+5.9%) |
| Mar 2013 | - | -$1.97 M(-12.7%) | -$8.13 M(-7.9%) |
| Dec 2012 | -$9.04 M(+14.8%) | -$2.26 M(+20.9%) | -$8.83 M(-2.2%) |
| Sep 2012 | - | -$1.87 M(-7.7%) | -$9.03 M(-3.7%) |
| Jun 2012 | - | -$2.03 M(-24.3%) | -$9.38 M(+27.6%) |
| Mar 2012 | - | -$2.67 M(+8.8%) | -$7.35 M(+57.2%) |
| Dec 2011 | -$7.87 M(+354.3%) | -$2.46 M(+11.0%) | -$4.67 M(+111.0%) |
| Sep 2011 | - | -$2.22 M | -$2.22 M |
| Dec 2010 | -$1.73 M | - | - |
FAQ
- What is RedHill Biopharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for RedHill Biopharma?
- What is RedHill Biopharma annual EBIT year-on-year change?
- What is the all time high quarterly EBIT for RedHill Biopharma?
- What is the all time high TTM EBIT for RedHill Biopharma?
What is RedHill Biopharma annual earnings before interest & taxes?
The current annual EBIT of RDHL is $24.28 M
What is the all time high annual EBIT for RedHill Biopharma?
RedHill Biopharma all-time high annual earnings before interest & taxes is $24.28 M
What is RedHill Biopharma annual EBIT year-on-year change?
Over the past year, RDHL annual earnings before interest & taxes has changed by +$54.62 M (+180.05%)
What is the all time high quarterly EBIT for RedHill Biopharma?
RedHill Biopharma all-time high quarterly earnings before interest & taxes is $50.66 M
What is the all time high TTM EBIT for RedHill Biopharma?
RedHill Biopharma all-time high TTM earnings before interest & taxes is $47.13 M